Viatris Financial Model
Pharmaceuticals Company Financials Example (Free Excel Download)
Viatris Inc. is a global healthcare company formed by the 2020 merger of Mylan and Pfizer's Upjohn business, bridging the gap between generic and branded pharmaceuticals.
professionals from Deloitte
Used by professionals from
About this model
This model evaluates the equity valuation and debt paydown trajectory of Viatris, enabling an analyst to assess whether the company's strong free cash flow generation and recent divestitures can offset base business price erosion and regulatory headwinds.
Viatris Inc. is a global healthcare company formed by the 2020 merger of Mylan and Pfizer's Upjohn business, bridging the gap between generic and branded pharmaceuticals. The company operates through four main geographic segments: Developed Markets (approx. 60% of revenue), Emerging Markets (approx. 15%), Greater China (approx. 15%), and JANZ (Japan, Australia, New Zealand; approx. 10%). Viatris operates a hybrid business model, manufacturing and distributing off-patent branded drugs, complex generics, and standard generics. The company holds a leading market position in global generics but faces intense competition from peers like Teva, Sandoz, and Organon. Recently, Viatris completed a major strategic transformation by divesting its biosimilars, Over-the-Counter (OTC), Women's Healthcare, and Active Pharmaceutical Ingredients (API) businesses to streamline operations and pay down debt.
The downloadable Viatris financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsViatris financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $17.81B | $16.22B | $15.39B | $14.69B | $14.25B |
| Gross profit | $5.58B | $6.50B | $6.44B | $5.62B | $5.01B |
| Operating income | -$34.0M | $1.61B | $766.2M | $10.1M | -$2.66B |
| Net income | -$1.27B | $2.08B | $54.7M | -$634.2M | -$3.51B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Viatris
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Developed Markets
- Segment name: Developed Markets
- Revenue driver formula: Base Business Volume x Price/Unit + New Product Launches
- Historical growth rate: -3% to 0% (impacted by divestitures and price erosion)
- Key growth levers and headwinds: Growth is driven by complex generics and new product launches (e.g., Breyna, lisdexamfetamine). Headwinds include standard generic price erosion and the recent FDA import alert at the Indore facility.
- Pricing dynamics: Highly competitive, with contractual pricing for large pharmacy benefit managers (PBMs) and wholesalers.
- Revenue recognition notes: Recognised upon transfer of control, net of variable consideration (rebates, chargebacks, and returns).
- Seasonality: Relatively stable, with slight upticks in Q1 and Q4 due to respiratory and cold/flu product demand.
Emerging Markets
- Segment name: Emerging Markets
- Revenue driver formula: Volume x Price/Unit + Tender Wins
- Historical growth rate: -12% reported in 2024 (heavily impacted by divestitures), underlying operational growth is low single digits.
- Key growth levers and headwinds: Expanding access to branded generics in developing nations. Headwinds include severe foreign exchange volatility and local regulatory shifts.
- Pricing dynamics: Spot pricing and government tenders; highly sensitive to local currency fluctuations.
- Revenue recognition notes: Standard point-in-time recognition, but subject to higher credit risk provisions.
- Seasonality: Minimal seasonality.
Greater China
- Segment name: Greater China
- Revenue driver formula: Volume x Price/Unit
- Historical growth rate: Flat to +2%
- Key growth levers and headwinds: Driven by retail channel expansion for legacy Upjohn brands (e.g., Lipitor, Norvasc). The primary headwind is the Volume-Based Procurement (VBP) programme, which forces massive price cuts for off-patent drugs.
- Pricing dynamics: Regulated by government VBP tenders; retail pricing offers a slight premium.
- Revenue recognition notes: Net of hospital and distributor rebates.
- Seasonality: Q4 is typically stronger due to hospital budget cycles.
JANZ (Japan, Australia, New Zealand)
- Segment name: JANZ
- Revenue driver formula: Volume x Price/Unit
- Historical growth rate: -5% to -2%
- Key growth levers and headwinds: Government price regulations in Japan (annual price cuts) are a persistent headwind, partially offset by volume growth in Australia.
- Pricing dynamics: Strictly regulated by national health systems with mandated annual or biennial price reductions.
- Revenue recognition notes: Standard point-in-time recognition.
- Seasonality: Minor fluctuations tied to the April implementation of Japanese price cuts.
Cost Structure
Variable Costs / COGS
- COGS includes raw materials, direct labour, manufacturing overhead, product supply costs, and regulatory remediation penalties (e.g., Indore facility costs).
- Gross margin range: GAAP gross margin runs 38-42%, while Adjusted Gross Margin runs 56-58%. The massive gap is due to the amortisation of acquired intangible assets and impairment charges.
- Key input costs include active pharmaceutical ingredients (APIs) and packaging.
- COGS scales linearly with volume, but gross margin percentage is highly dependent on product mix (brands yield higher margins than standard generics).
Operating Expenses
- R&D: Typically 4-5% of revenue. Covers clinical trials for complex generics and innovative assets. Expected to increase by over $100 million in 2025 due to the Idorsia collaboration.
- SG&A: Typically 20-25% of revenue. Includes a massive global sales force, marketing for legacy brands, and corporate overhead.
- Depreciation & Amortisation: Extremely high (approx. 15-20% of revenue) due to the Upjohn merger and historical Mylan acquisitions. Mostly intangible amortisation.
- Stock-Based Compensation: Approximately 1-2% of revenue.
- Restructuring / one-time charges: Frequent and material. The company regularly reports restructuring costs, litigation settlements, and divestiture-related transaction costs.
Margin Profile
- Gross margin (Adjusted): 56-58%
- EBITDA margin (Adjusted): 31-33%
- Operating margin (GAAP): Often low single digits or negative due to amortisation and impairments.
- Margin trend: Compressing slightly due to the Indore facility remediation (approx. $385 million EBITDA impact expected in 2025) and standard price erosion, offset by cost-saving initiatives.
Balance Sheet Structure
- Total assets: Approximately $35-40 billion.
- Key asset categories: Intangible assets and goodwill make up the vast majority of assets, stemming from the Upjohn and Meda transactions.
- Goodwill & intangibles as % of total assets: Typically 60-70%.
- Working capital profile:
- Days Sales Outstanding (DSO): 60-75 days.
- Days Inventory Outstanding (DIO): 90-110 days (pharma requires high safety stock).
- Days Payable Outstanding (DPO): 50-65 days.
- Net working capital as % of revenue: 15-20%.
- Working capital is generally positive and represents a use of cash as the business grows.
- PP&E: Approximately 10-15% of assets, representing global manufacturing facilities.
- Right-of-use assets: Material but not a primary driver of leverage.
Capital Expenditure & Investment
- Capex as % of revenue: 2.0-3.0% (approx. $300-$400 million annually).
- Maintenance capex vs. growth capex: Roughly 70% maintenance (facility upgrades, compliance) and 30% growth (new manufacturing lines for complex products).
- Major capex programmes: Remediation and upgrades at the Indore facility and other global sites.
- M&A pattern: Historically a transformational acquirer (Mylan + Upjohn), but currently focused on divestitures and organic pipeline licensing (e.g., Idorsia, Lexicon Pharmaceuticals).
Debt & Capital Structure
- Total debt: Approximately $14.9 billion (notional amount as of late 2024).
- Debt/EBITDA ratio: Target is 3.0x gross leverage; achieved 2.9x at the end of 2024.
- Credit rating: Investment grade (BBB- / Baa3).
- Key debt instruments: Senior notes (USD and EUR denominated) and a revolving credit facility.
- Maturity profile: Staggered, with the company actively using free cash flow to retire near-term maturities (paid down $3.7 billion in 2024).
- Interest rate profile: Predominantly fixed-rate bonds.
- Covenants: Standard leverage and interest coverage covenants on the revolving credit facility.
- Share repurchase programme: Active. Authorised up to $2.0 billion, with $500-$650 million targeted for 2025.
- Dividend policy: $0.48 per share annually ($0.12 quarterly), yielding approx. 3-4%.
Cash Flow Characteristics
- Operating cash flow conversion: Very strong. OCF is typically $2.3-$2.8 billion annually.
- Free cash flow margin: 13-17% (FCF of approx. $2.0-$2.6 billion on $14.7 billion revenue).
- Major non-cash items: Intangible amortisation, goodwill impairments, and deferred taxes bridge the GAAP net loss to strong positive OCF.
- Working capital cash flow impact: Fluctuates based on inventory builds for new product launches.
- Capex intensity: Low (asset-light relative to cash generation).
- Cash tax rate vs. GAAP effective tax rate: Cash taxes are typically lower than the statutory rate due to the global jurisdictional mix and utilisation of deferred tax assets.
Sheet Structure
- Assumptions: Hardcoded inputs for macroeconomic drivers, segment growth rates, margin profiles, tax rates, and capital allocation policies.
- Revenue Build: Detailed build for Developed Markets, Emerging Markets, Greater China, and JANZ. Includes a separate schedule for New Product Revenues and the negative overlay for the Indore facility impact.
- Income Statement: GAAP to Non-GAAP bridge. Must explicitly show Gross Profit, SG&A, R&D, Amortisation, and Restructuring to arrive at Adjusted EBITDA and GAAP Net Income.
- Balance Sheet: Assets (cash, AR, inventory, PP&E, massive intangibles/goodwill), Liabilities (AP, accrued expenses, short-term debt, long-term debt), and Equity.
- Cash Flow Statement: Operating, Investing, and Financing cash flows. Must clearly show the add-back of amortisation and the deduction of dividends and share repurchases.
- Debt Schedule: Tranche-by-tranche breakdown of senior notes, mandatory repayments, discretionary paydowns, and interest expense calculation.
- Working Capital Schedule: DSO, DIO, and DPO calculations linking the Income Statement to the Balance Sheet.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, terminal value, and implied share price.
Key Financial Relationships
- `Developed Markets Revenue = Prior Year Developed Markets Revenue * (1 + Developed Markets Growth Rate) + New Product Contribution`
- `Total Revenue = Developed Markets Revenue + Emerging Markets Revenue + Greater China Revenue + JANZ Revenue - Indore Facility Revenue Impact`
- `Adjusted Gross Profit = Total Revenue * Adjusted Gross Margin %`
- `GAAP Gross Profit = Adjusted Gross Profit - Amortisation of Acquired Intangibles - Indore Remediation Penalties`
- `R&D Expense = Total Revenue * R&D % + Idorsia Collaboration Incremental Cost`
- `Adjusted EBITDA = Total Revenue * Adjusted EBITDA Margin % - Indore EBITDA Impact`
- `Free Cash Flow = Operating Cash Flow - Capital Expenditures`
- `Gross Leverage Ratio = Total Notional Debt / Adjusted EBITDA`
- `Interest Expense = Average Debt Balance * Weighted Average Interest Rate`
- `Ending Share Count = Beginning Share Count - (Share Repurchase Amount / Average Share Price)`
- `Total Dividends Paid = Ending Share Count * Annual Dividend Per Share`
Cross-Sheet Dependencies
- The Assumptions sheet feeds the Revenue Build and Income Statement margins.
- The Revenue Build feeds the top line of the Income Statement.
- Income Statement net income and non-cash add-backs (amortisation) feed the Cash Flow Statement.
- The Working Capital Schedule uses revenue and COGS from the Income Statement to calculate AR, AP, and Inventory on the Balance Sheet, which in turn drives the working capital changes on the Cash Flow Statement.
- The Debt Schedule uses Free Cash Flow from the Cash Flow Statement to determine discretionary debt paydown, which updates the debt balances on the Balance Sheet and calculates interest expense for the Income Statement. This creates a circular reference that must be managed with a circuit breaker toggle.
Sign Convention
- Income Statement: Revenues are positive. All expenses (COGS, SG&A, R&D, Interest, Taxes) are negative. Net Income is positive if profitable, negative if a loss.
- Balance Sheet: Assets are positive. Liabilities and Equity are positive.
- Cash Flow Statement: Cash inflows (e.g., Net Income, Amortisation, Debt Issuance) are positive. Cash outflows (e.g., Capex, Working Capital increases, Debt Repayment, Dividends) are negative.
Things Most Likely to Go Wrong
- The company reports massive GAAP net losses due to intangible amortisation, but generates billions in free cash flow. Failing to bridge GAAP Net Income to Adjusted EBITDA correctly will break the cash flow statement.
- The Indore facility warning letter has a specific, hardcoded impact for 2025 ($500 million revenue hit, $385 million EBITDA hit). This must be modelled as a discrete overlay, not blended into a generic growth rate.
- Viatris divested its OTC, Women's Health, and API businesses in 2024. Historical 2023 and early 2024 data includes these revenues. The model must use "divestiture-adjusted" base rates for forecasting to avoid overstating future revenue.
- Foreign currency translation heavily impacts Emerging Markets and JANZ. The model should forecast on a constant-currency basis and apply a separate FX overlay if needed.
- Gross margin has a 15-20% gap between GAAP and Non-GAAP. The builder must ensure COGS in the GAAP Income Statement includes the amortisation of acquired inventory step-up and intangibles.
- Debt paydown is the primary use of cash. If the model does not automatically sweep excess cash to the Debt Schedule, the cash balance will balloon unrealistically.
- Share repurchases reduce the share count, which impacts the total dividend payout calculation. Ensure the dividend formula references the dynamic share count.
- R&D expenses will step up materially in 2025 due to the Idorsia partnership. Using a historical average R&D margin will understate 2025 costs.
Validation Checks
- Gross Leverage Ratio must not exceed 3.0x; flag if it does.
- Adjusted Gross Margin should remain in the 56-58% band.
- Free Cash Flow must be positive and generally exceed $2.0 billion annually.
- Capex as a percentage of revenue should remain between 2.0% and 3.0%.
- The Balance Sheet must balance: Total Assets = Total Liabilities + Shareholders' Equity in all forecast periods.
- Dividend payout must equal exactly $0.48 per share annually.
- R&D expense for 2025 must show a minimum $100 million year-over-year increase.
- Total Revenue for 2025 should reconcile closely to the company's guidance midpoint of $13.75 billion.
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Developed Markets Base Growth | -1.5 | % | Reflects standard generic price erosion offset by slight volume growth. |
| Emerging Markets Base Growth | 2.0 | % | Modest constant-currency growth excluding divestitures. |
| Greater China Base Growth | 1.0 | % | Stable retail demand offsetting VBP pricing pressure. |
| JANZ Base Growth | -3.0 | % | Ongoing impact of Japanese government price cuts. |
| 2025 Indore Revenue Impact | -500 | USD Millions | Explicit company guidance for 2025 FDA import alert impact. |
| 2025 Indore EBITDA Impact | -385 | USD Millions | Explicit company guidance for 2025 margin impact. |
| New Product Revenue (2025) | 500 | USD Millions | Midpoint of $450M-$550M company guidance. |
| Adjusted Gross Margin | 56.5 | % | Historical average adjusted for Indore penalty dilution. |
| SG&A as % of Revenue | 22.5 | % | Historical average, reflecting global commercial infrastructure. |
| R&D as % of Revenue | 5.0 | % | Elevated slightly to account for Idorsia collaboration. |
| Capex as % of Revenue | 2.5 | % | Midpoint of $300M-$400M guidance on ~$14B revenue. |
| Days Sales Outstanding (DSO) | 65 | Days | Based on historical receivables turnover. |
| Days Inventory Outstanding (DIO) | 100 | Days | Based on historical inventory levels required for global supply. |
| Days Payable Outstanding (DPO) | 55 | Days | Based on historical payable terms. |
| Weighted Average Interest Rate | 4.5 | % | Blended rate on existing fixed-rate senior notes. |
| Adjusted Effective Tax Rate | 16.0 | % | Management guidance for non-GAAP tax rate. |
| Annual Dividend Per Share | 0.48 | USD | Stated company dividend policy. |
| 2025 Share Repurchases | 575 | USD Millions | Midpoint of $500M-$650M company guidance. |
| WACC | 8.5 | % | Standard discount rate for large-cap generic pharma. |
| Terminal Growth Rate | 0.0 | % | Reflects long-term generic price erosion offsetting volume growth. |
Data Sources & Benchmarks
- SEC EDGAR: Viatris (VTRS) 10-K and 10-Q filings for historical segment data and debt schedules.
- Investor Relations: Viatris Q4 2024 Earnings Presentation for 2025 guidance, Indore impact, and divestiture reconciliations.
- Key Peers: Teva Pharmaceutical Industries (TEVA), Sandoz Group AG (SDZ), Organon & Co. (OGN), Perrigo (PRGO).
- Industry Data: IQVIA for global prescription volume trends and generic pricing indices.
- Consensus Estimates: FactSet or Bloomberg for checking model outputs against street expectations for Adjusted EBITDA and Free Cash Flow.
Sources
Do more with the Viatris model
Frequently asked
What kind of company is Viatris and what products do they offer?+
Viatris Inc. is a global healthcare company formed by the 2020 merger of Mylan and Pfizer's Upjohn business. It operates a hybrid business model, manufacturing and distributing off-patent branded drugs, complex generics, and standard generics.
How does Viatris generate its revenue across different geographic segments?+
Viatris generates its revenue primarily through its Developed Markets segment, which accounts for approximately 60% of its total revenue. Emerging Markets and Greater China each contribute about 15%, while JANZ (Japan, Australia, New Zealand) makes up roughly 10% of its revenue.
What are Viatris's typical capital expenditure requirements?+
Viatris typically allocates 2.0-3.0% of its revenue to capital expenditures annually, amounting to approximately $300-$400 million. Roughly 70% of this capex is for maintenance, such as facility upgrades, and 30% is for growth, like new manufacturing lines for complex products.
What are the main cost components for Viatris, according to its financial model assumptions?+
The financial model indicates that Cost of Goods Sold (COGS) represents approximately 64.7% of Viatris's revenue. Selling, General & Administrative (SGA) expenses are around 25.7% of revenue, and Research & Development (R&D) accounts for about 5.6%.
What is the primary objective of the Viatris financial model?+
The Viatris financial model aims to evaluate the company's equity valuation and its debt paydown trajectory. It helps analysts assess whether Viatris's strong free cash flow generation and recent divestitures can offset challenges like base business price erosion and regulatory headwinds.
Can I download an Excel financial model for Viatris (VTRS)?+
Yes, an Excel financial model for Viatris (VTRS) is available for download. This general corporate model provides a forecast horizon from FY2026 to FY2030, allowing for detailed analysis of the company's future financial performance.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Pharmaceuticals Company Financial Models
Browse another company in the same sector.
AbbVie
AbbVie is a global, research-based biopharmaceutical company that discovers and delivers innovative medicines and aesthetic products.
Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics, focusing on areas of high unmet medical need.
Biogen
Biogen is a global biotechnology company that discovers, develops, and delivers therapies for neurological, immunological, and rare diseases, including multiple sclerosis and Alzheimer's treatments.
Bristol Myers Squibb
Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercialises innovative medicines in areas of unmet medical need.
Incyte
Incyte Corporation is a global commercial-stage biopharmaceutical company focused on the discovery, development, and commercialisation of proprietary therapeutics, primarily in haematology, oncology, and inflammation and autoimmunity (IAI).
Johnson & Johnson
Johnson & Johnson is a diversified global healthcare leader engaged in the research, development, manufacture, and sale of pharmaceutical products and medical devices.
Lilly (Eli)
Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and markets human medicines, with a dominant focus on cardiometabolic diseases, oncology, immunology, and neuroscience.
Explore more Healthcare financial model templates.
